Natale Alessio, Brunetti Tullio, Orioni Gionathan, Gaspari Valeria
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, 40138 Bologna, Italy.
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy.
J Clin Med. 2024 Sep 4;13(17):5246. doi: 10.3390/jcm13175246.
Over the last decades, the incidence of anal cancer has increased worldwide. The discovery of the HPV virus as its primary cause and the natural progression of the disease, involving precancerous lesions, have resulted in significant interest in screening for anal cancer. The use of cytology testing, high-risk HPV DNA research, high-resolution anoscopy, and their combination has been adopted with variable success in detecting anal HPV precancerous lesions. Various studies have been carried out to evaluate the sensitivity and specificity of these techniques in different populations. High-risk populations for developing anal cancer have been identified through study of incidence and prevalence. Therefore, different scientific societies and experts worldwide have provided different recommendations for screening, but a universal approach has not yet been established. The inhomogeneity of different risk groups, the variable accessibility to specifical techniques, and the lack of data regarding the cost-benefit ratio of screening are the main problems to address in order to define a consensus guideline acceptable worldwide. The purpose of this paper is to provide a comprehensive review of the literature on HPV precancerous lesions and its screening, particularly after the release of recent recommendations.
在过去几十年中,肛门癌的发病率在全球范围内呈上升趋势。人乳头瘤病毒(HPV)被发现是其主要病因,且该疾病会经历包括癌前病变在内的自然发展过程,这使得人们对肛门癌筛查产生了浓厚兴趣。细胞学检测、高危型HPV DNA检测、高分辨率肛门镜检查及其联合应用在检测肛门HPV癌前病变方面取得了不同程度的成功。人们开展了各种研究来评估这些技术在不同人群中的敏感性和特异性。通过对发病率和患病率的研究,已确定了患肛门癌的高危人群。因此,世界各地不同的科学协会和专家给出了不同的筛查建议,但尚未形成统一的方法。不同风险群体的异质性、特定技术的可及性差异以及筛查成本效益比方面缺乏数据,是为制定全球可接受的共识指南而需解决的主要问题。本文的目的是对HPV癌前病变及其筛查的文献进行全面综述,尤其是在近期相关建议发布之后。